$246 Million is the total value of Knoll Capital Management, LLC's 22 reported holdings in Q1 2016. The portfolio turnover from Q4 2015 to Q1 2016 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDVN | Medivation, Inc. | $202,213,000 | -4.9% | 4,397,838 | 0.0% | 82.11% | +4.2% | |
| SYN | Synthetic Biologics Inc. | $8,813,000 | +3.1% | 3,734,149 | 0.0% | 3.58% | +12.9% | |
| AMPE | Ampio Pharmaceuticals Inc. | $7,624,000 | -35.7% | 3,388,322 | 0.0% | 3.10% | -29.6% | |
| CRBP | Corbus Pharmaceuticals HLDGS | $4,641,000 | +9.7% | 2,563,925 | 0.0% | 1.88% | +20.2% | |
| ADHD | Alcobra Ltd | $4,227,000 | -39.6% | 1,115,315 | 0.0% | 1.72% | -33.9% | |
| ABEO | Abeona Therapeutics Inc | $3,481,000 | -23.8% | 1,359,767 | 0.0% | 1.41% | -16.6% | |
| CEMP | Cempra Inc | $3,168,000 | -43.7% | 180,800 | 0.0% | 1.29% | -38.4% | |
| NLNK | Newlink Genetics Corp | $1,864,000 | -50.0% | 102,437 | 0.0% | 0.76% | -45.2% | |
| Vascular Biologics LTD | $1,160,000 | -33.8% | 333,332 | 0.0% | 0.47% | -27.5% | ||
| KERX | Keryx Biopharmaceuticals Inc. | $934,000 | -7.5% | 200,000 | 0.0% | 0.38% | +1.3% | |
| OHRP | OHR Pharmaceutical Inc | $658,000 | -47.7% | 205,000 | 0.0% | 0.27% | -42.8% | |
| ALDX | Aldeyra Therapeutics Inc | $569,000 | -38.2% | 135,800 | 0.0% | 0.23% | -32.3% | |
| CLBS | Caladrius Biosciences Inc | $417,000 | -30.5% | 555,781 | 0.0% | 0.17% | -23.9% | |
| CSBR | Champions Oncology INC | $405,000 | +2.0% | 111,111 | 0.0% | 0.16% | +11.6% | |
| GLMD | Galmed Pharmaceuticals Ltd | $320,000 | -35.4% | 65,000 | 0.0% | 0.13% | -29.3% | |
| EVOK | Evoke Pharma Inc | $283,000 | +53.8% | 55,660 | 0.0% | 0.12% | +69.1% | |
| ZSAN | Zosano Pharma Corp | $43,000 | +2.4% | 18,600 | 0.0% | 0.02% | +6.2% | |
| Aptose Biosciences Inc | $34,000 | +9.7% | 11,933 | 0.0% | 0.01% | +27.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Aldeyra Therapeutics Inc | 35 | Q3 2023 | 31.6% |
| Corbus Pharmaceuticals HLDGS | 30 | Q3 2022 | 46.5% |
| Abeona Therapeutics Inc | 30 | Q3 2022 | 34.8% |
| Biohaven Pharmactl Hldg Co L | 26 | Q3 2023 | 79.6% |
| Entera Bio Ltd | 22 | Q3 2023 | 7.8% |
| Ampio Pharmaceuticals Inc. | 21 | Q2 2018 | 11.0% |
| Soligenix Inc. | 20 | Q3 2022 | 1.7% |
| Eiger Biopharmaceuticals Inc | 19 | Q3 2022 | 5.8% |
| Applied Therapeutics Inc | 18 | Q3 2023 | 19.7% |
| Alcobra Ltd | 18 | Q3 2017 | 6.5% |
View Knoll Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| HOOKIPA Pharma Inc. | June 20, 2023 | 5,517,385 | 6.8% |
| Applied Therapeutics Inc. | January 23, 2023 | 3,450,000 | 7.2% |
| Orgenesis Inc. | August 14, 2020 | 1,316,364 | 5.9% |
| Corbus Pharmaceuticals Holdings, Inc. | February 14, 2020 | 5,045,870 | 7.1% |
| ABEONA THERAPEUTICS INC. | February 14, 2018 | 2,359,767 | 5.0% |
| SOLIGENIX, INC. | November 13, 2017 | 870,000 | 9.9% |
| ABEONA THERAPEUTICS INC. | February 14, 2017 | 2,359,767 | 5.9% |
| ALCOBRA LTD. | February 14, 2017 | 1,205,498 | 4.4% |
| Ampio Pharmaceuticals, Inc. | February 14, 2017 | 2,738,322 | 4.8% |
| RITTER PHARMACEUTICALS INC | February 14, 2017 | 952,434 | 8.2% |
View Knoll Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-01-16 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-04 |
| 13F-HR | 2023-08-15 |
| SC 13G | 2023-06-20 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-23 |
View Knoll Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.